PFA for persistent AF: benefits, evidence and treatment planning

Your AF pattern changes which evidence applies and which treatment areas are covered by the device indication. ADVENT studied paroxysmal AF; ADVANTAGE AF provides separate evidence for persistent AF. Persistent AF is not evidence that PFA cannot help, but the paroxysmal-AF percentage is not a personal forecast for it. [1][2][3]

Paroxysmal and persistent AF are not interchangeable

In the ADVENT protocol, paroxysmal AF ended spontaneously or with an intervention within seven days of onset. Persistent AF, including continuous episodes longer than seven days, was excluded. ADVENT enrolled symptomatic patients whose antiarrhythmic drug treatment had failed through lack of effect or intolerance—not every person with AF. [4]

AF classification is based on the duration and course of episodes, not simply how often you feel palpitations. A timeline of episodes, cardioversions and medicines tried, together with rhythm recordings, gives the electrophysiologist the information needed to place your history in the appropriate study population. [4]

What ADVENT can—and cannot—answer

ADVENT randomized 305 patients to PFA and 302 to thermal ablation. Its FARAPULSE comparison pooled radiofrequency and cryoballoon treatment in the thermal arm. At one year, primary effectiveness was estimated at 73.3% with PFA and 71.3% with thermal ablation. This composite included procedural success and freedom from specified recurrence or further treatment after the blanking period; it was not a simple lifetime cure rate. [1][4]

The conclusion was noninferiority to pooled thermal ablation, not superiority over radiofrequency or cryoballoon individually. The trial does not supply an expected success percentage for persistent AF or for another PFA platform. [1][4]

The separate persistent-AF evidence: ADVANTAGE AF

ADVANTAGE AF was a prospective, multicentre, single-arm study of the FARAPULSE pentaspline catheter for persistent AF. It treated the pulmonary veins plus the posterior wall. There were 339 patients overall: 260 treatment patients and 79 roll-in patients. There was no randomized thermal control group. [2]

At one year, the primary effectiveness estimate was 63.5%, with a 97.5% one-sided lower confidence limit of 57.3%. The endpoint combined acute success with postblanking freedom from atrial tachyarrhythmia lasting more than 30 seconds, repeat ablation, cardioversion or antiarrhythmic-drug escalation. This Kaplan–Meier estimate is not a raw fraction of everyone enrolled and not a promise for an individual. [2]

Monitoring included 24-hour Holter recordings at six and twelve months, plus twice-monthly and symptom-triggered telephone transmissions. This was not continuous implanted monitoring. Freedom from symptomatic AF was reported separately at 85.3%; having no symptoms and meeting the stricter primary endpoint are different outcomes. [2]

The primary safety estimate was 2.3%, with a 97.5% one-sided upper confidence limit of 5.1%. A single-arm study cannot establish that this is safer than thermal ablation. Nor should 63.5% in persistent AF be ranked against ADVENT’s 73.3% in paroxysmal AF: the populations, lesion sets and study designs differ. These are one-year results, not lifetime guarantees. [2][1]

Match the evidence to the device and local indication

The FDA supplement dated January 12, 2026 specifies FARAWAVE pulmonary-vein isolation for drug-refractory, recurrent, symptomatic paroxysmal AF, and pulmonary-vein plus posterior-wall isolation for drug-refractory, symptomatic persistent AF with episode duration less than one year. That US device-specific indication does not authorize every PFA system, every treatment pattern or every duration of persistent AF. This is a US indication; it does not establish the regulatory indication in another country. [3]

Move from a study result to an individual treatment plan

For persistent AF, the evidence described here concerns FARAPULSE treatment of both the pulmonary veins and posterior wall. For paroxysmal AF, ADVENT evaluated pulmonary-vein isolation. An assessment connects your episode history and prior treatment to a proposed device and treatment area; follow-up rhythm monitoring then distinguishes symptom relief from documented recurrence. Further medicines, cardioversion or repeat ablation may still be needed—these were part of the study’s effectiveness endpoint, not proof of a permanent cure. [1][2][3]

Use the official Cleveland Clinic assessment link below to start an arrhythmia consultation, or use Bookimed’s assessment-support button to request coordination. Prepare your rhythm recordings, episode timeline and medicine list for the consultation, and obtain a written treatment and follow-up plan before arranging travel. The assessment link is not confirmation of a particular campus, device, operator or booking through Bookimed. [5]

What Bookimed can help with

Bookimed coordinators can help match hospitals and doctors, request individual treatment programmes and arrange a second medical opinion. Bookimed does not provide medical advice. These services do not guarantee PFA eligibility, a named clinician, availability at a particular clinic or a treatment price. [6]

Discuss an individual assessment

Ask an electrophysiologist to check your AF pattern, proposed device and treatment plan. You can send a request through Bookimed; this is not a booking confirmation, medical advice or a guarantee of PFA eligibility at any named clinic.

Request assessment support

Bookimed can help coordinate an assessment. Provider listings do not guarantee availability through Bookimed or an individual treatment price.